One plan - full access

No subscription, no auto-renewal, no hidden terms.
Pay once and use it for 30 days.

PRO plan No auto-renewal
$18

30 days of full access
One-time payment

🌐 US & Global Companies
Get access for 30 days →
♧ Secure payment · Instant access

What is included

  • ✓Full access to detailed company analysis
  • ✓Fundamental screener
  • ✓Advanced stock screener filters
  • ✓5 ratings. Separate lists for US & Global Companies and MOEX
  • ✓Company data export in XLSX and CSV
  • ✓MarketCap’s overall ranking of top companies
  • ✓Analytics updates after each new financial report
⚠ The service is not an investment advisor. Financial statement data from public companies is available to everyone - MarketCap structures and analyzes it.
Genfit SA logo
Genfit SA GNFT
report update icon

Quarterly report 2024-Q4
added 11-07-2026

Genfit SA Income Statement 2024-2011 | GNFT

Brief overview of financial performance at Genfit SA

The comparison covers a five-year financial horizon. Revenue at Genfit SA moved from 41 million euros in 2019 to 70.9 million euros in 2024. Overall revenue changed by +73.2%, equal to an annualized rate of about 11.6%. The trajectory reflects meaningful expansion of the business.

EBITDA was −57.8 million euros at the beginning and 3.3 million euros at the end of the period (+105.7%). The operating result outpaced sales and points to improving efficiency. At the operating-margin level, the figure shifted from −141.2% to 4.6%. Higher profitability strengthens the quality of operating growth.

The net financial result changed from −65.1 million euros to 1.5 million euros. The business moved out of a loss and ended the period with a profit.

Over the period, capitalization shifted from 567 million euros to 167 billion euros (+29381.6%). Capitalization moved ahead of the business fundamentals.

Conclusion

The five-year picture requires weighing both strengths and weaknesses. Key strengths include positive operating leverage, revenue expansion and a stronger final result. The main areas of concern are a narrow EBITDA buffer. Future reports should be judged by revenue momentum, margins, and the conversion of sales into net income.

Annual Income Statement Genfit SA

2024 2023 2022 2021 2020 2019 2018 2017 2016 2015 2014 2013 2012 2011

Market Cap

167 B 178 B 178 B 168 B 185 M 567 M - - - - - - - -

Shares

49.8 B 49.7 B 49.7 B 44.7 B 37 M 37 M - - - - - - - -

Historical Prices

3.36 3.58 3.58 3.75 5 15.3 - - - - - - - -

Net Income

1.51 M -28.9 M -23.7 M 67.3 M -101 M -65.1 M -79.5 M -58.6 M -33.7 M -17.1 M -17 M -12.7 M -5.41 M -9.68 M

Revenue

70.9 M 38.2 M 26.6 M 85.6 M 7.76 M 41 M 7.49 M 6.86 M 284 K 527 K 1.61 M 1.9 M 1.67 M 2.36 M

Gross Profit

- - - - - - 5.51 M -2.11 M -1.7 M -1.4 M 210 K 606 K 477 K 949 K

Operating Income

3.28 M -26.6 M -27.3 M 31.8 M -82.9 M -57.8 M -69.5 M -56.7 M - - - - - -

Interest Expense

4.68 M 4.55 M 4.34 M 4.85 M 11.6 M 11.3 M 11 M 2.31 M - - - - - -

EBITDA

3.28 M -26.6 M -27.3 M 31.8 M -82.9 M -57.8 M -69.5 M -56.7 M -33.4 M -17.2 M -17 M -9.94 M -7 M -6.99 M

Operating Expenses

-3.28 M 26.6 M 27.3 M - 78.3 M 111 M 91 M 54.6 M 32.5 M 16.3 M 17.5 M 11 M 8.19 M 8.7 M

General and Administrative Expenses

19.5 M 17.7 M 16.4 M 16.2 M 7.14 M 17.3 M 13.6 M 13.4 M 11.7 M 9.13 M 9.37 M 7.38 M 6.45 M 6.02 M

All numbers in EUR currency

Quarterly Income Statement Genfit SA

2024-Q4 2023-Q4 2023-Q2 2022-Q4 2022-Q3 2022-Q2 2022-Q1 2021-Q4 2021-Q3 2021-Q2 2021-Q1 2020-Q4 2020-Q3 2020-Q2 2020-Q1 2019-Q4 2019-Q3 2019-Q2 2019-Q1 2018-Q4 2018-Q3 2018-Q2 2018-Q1 2017-Q4 2017-Q3 2017-Q2 2017-Q1 2016-Q4 2016-Q3 2016-Q2 2016-Q1 2015-Q4 2015-Q3 2015-Q2 2015-Q1 2014-Q4 2014-Q3 2014-Q2 2014-Q1 2013-Q4 2013-Q3 2013-Q2 2013-Q1 2012-Q4 2012-Q3 2012-Q2 2012-Q1 2011-Q4 2011-Q3 2011-Q2 2011-Q1

All numbers in EUR currency

The income statement is one of the three key financial reports of a company Genfit SA (alongside the balance sheet and the cash flow statement). It shows how the company makes money and what its expenses are:

  • How much revenue the company earned
  • How much it spent on production, personnel, marketing, taxes, etc.
  • What profit remained in the end

Analyzing the income statement helps an investor understand whether the business generates stable and growing profits, how effectively the company controls its expenses, and whether it is capable of generating income in the future. Additionally, this analysis shows how the company copes with crises and economic cycles, and allows assessing the potential for stock price growth and dividend payments.

Features
  • The income statement may include both recurring and one-time items (for example, profit from the sale of assets). It is necessary to separate core metrics from one-off events for accurate analysis.
  • Companies often publish interim reports (e.g., quarterly), which allows for more timely tracking of trends.
  • A combined analysis of the income statement with the balance sheet and cash flow statement provides a comprehensive view of the company’s financial health.

Reports on the profits and losses of other stocks in the Biotechnology industry

Issuer Price % 24h Market Cap Country
Five Prime Therapeutics, Inc. Five Prime Therapeutics, Inc.
FPRX
- - $ 1.77 B usaUSA
ADC Therapeutics SA ADC Therapeutics SA
ADCT
$ 1.59 -2.16 % $ 202 M schweizSchweiz
Harmony Biosciences Holdings Harmony Biosciences Holdings
HRMY
$ 33.1 1.96 % $ 1.9 B usaUSA
Ardelyx Ardelyx
ARDX
$ 2.88 -3.85 % $ 694 M usaUSA
Akebia Therapeutics Akebia Therapeutics
AKBA
$ 0.39 -7.57 % $ 100 M usaUSA
Alector Alector
ALEC
$ 2.3 9.81 % $ 237 M usaUSA
ALX Oncology Holdings ALX Oncology Holdings
ALXO
$ 1.16 0.43 % $ 62.2 M usaUSA
Amneal Pharmaceuticals Amneal Pharmaceuticals
AMRX
$ 20.13 3.5 % $ 6.31 B usaUSA
Arbutus Biopharma Corporation Arbutus Biopharma Corporation
ABUS
$ 3.65 -0.54 % $ 699 M canadaCanada
Agenus Agenus
AGEN
$ 7.13 10.71 % $ 212 M usaUSA
AbCellera Biologics AbCellera Biologics
ABCL
$ 11.89 6.83 % $ 3.55 B canadaCanada
Artelo Biosciences Artelo Biosciences
ARTL
$ 1.98 -6.62 % $ 375 K usaUSA
Immatics N.V. Immatics N.V.
IMTX
$ 6.36 2.91 % $ 778 M germanyGermany
Aptevo Therapeutics Aptevo Therapeutics
APVO
$ 1.24 -2.36 % $ 391 K usaUSA
Aligos Therapeutics Aligos Therapeutics
ALGS
$ 4.14 -8.2 % $ 40.9 M usaUSA
Aclaris Therapeutics Aclaris Therapeutics
ACRS
$ 3.9 8.03 % $ 478 M usaUSA
Adaptive Biotechnologies Corporation Adaptive Biotechnologies Corporation
ADPT
$ 27.98 4.29 % $ 4.25 B usaUSA
Cellectar Biosciences Cellectar Biosciences
CLRB
$ 1.24 7.83 % $ 3.23 M usaUSA
Larimar Therapeutics Larimar Therapeutics
LRMR
$ 2.4 3.23 % $ 199 M usaUSA
Biofrontera AG Biofrontera AG
BFRA
- -8.24 % $ 105 M germanyGermany
Catabasis Pharmaceuticals, Inc. Catabasis Pharmaceuticals, Inc.
CATB
- -6.97 % $ 657 M usaUSA
Capricor Therapeutics Capricor Therapeutics
CAPR
$ 8.97 4.3 % $ 417 M usaUSA
Amphastar Pharmaceuticals Amphastar Pharmaceuticals
AMPH
$ 28.5 3.04 % $ 1.33 B usaUSA
China Biologic Products Holdings, Inc. China Biologic Products Holdings, Inc.
CBPO
- 1.68 % $ 4.65 B chinaChina
Aquestive Therapeutics Aquestive Therapeutics
AQST
$ 3.6 -1.64 % $ 385 M usaUSA
Jaguar Health Jaguar Health
JAGX
$ 0.4 -2.16 % $ 933 K usaUSA
Arvinas Arvinas
ARVN
$ 6.41 -2.14 % $ 454 M usaUSA
Cerus Corporation Cerus Corporation
CERS
$ 2.03 -4.93 % $ 387 M usaUSA
Beam Therapeutics Beam Therapeutics
BEAM
$ 26.43 2.15 % $ 2.61 B usaUSA
Fortress Biotech Fortress Biotech
FBIO
$ 1.86 0.82 % $ 51.9 M usaUSA
Inhibrx Inhibrx
INBX
$ 84.71 5.52 % $ 3.99 B usaUSA
Entera Bio Ltd. Entera Bio Ltd.
ENTX
$ 3.16 5.69 % $ 146 M israelIsrael
Flexion Therapeutics, Inc. Flexion Therapeutics, Inc.
FLXN
- - $ 459 M usaUSA
Legend Biotech Corporation Legend Biotech Corporation
LEGN
$ 23.43 3.95 % $ 8.64 B usaUSA
CytomX Therapeutics CytomX Therapeutics
CTMX
$ 2.19 2.1 % $ 302 M usaUSA
Krystal Biotech Krystal Biotech
KRYS
$ 300.7 0.15 % $ 8.7 B usaUSA
Kura Oncology Kura Oncology
KURA
$ 7.15 5.15 % $ 627 M usaUSA
Inhibikase Therapeutics Inhibikase Therapeutics
IKT
$ 1.5 4.17 % $ 147 M usaUSA
Heron Therapeutics Heron Therapeutics
HRTX
$ 0.29 2.25 % $ 48.3 M usaUSA
Inovio Pharmaceuticals Inovio Pharmaceuticals
INO
$ 1.22 -16.21 % $ 57.2 M usaUSA
Corvus Pharmaceuticals Corvus Pharmaceuticals
CRVS
$ 10.56 8.5 % $ 834 M usaUSA
Aytu BioScience Aytu BioScience
AYTU
$ 1.82 0.55 % $ 22.4 M usaUSA
Heat Biologics, Inc. Heat Biologics, Inc.
HTBX
- -5.76 % $ 99.8 M usaUSA
Innoviva Innoviva
INVA
$ 19.09 -0.78 % $ 1.29 B usaUSA
BioCardia BioCardia
BCDA
$ 0.86 -3.12 % $ 5.73 M usaUSA
Kindred Biosciences, Inc. Kindred Biosciences, Inc.
KIN
- 0.11 % $ 419 M usaUSA
Alterity Therapeutics Limited Alterity Therapeutics Limited
ATHE
$ 2.44 9.91 % $ 15.6 B australiaAustralia
Shineco, Inc. Shineco, Inc.
TYHT
- -3.90 % $ 97.2 M chinaChina
Millendo Therapeutics, Inc. Millendo Therapeutics, Inc.
MLND
- -5.36 % $ 20.2 M usaUSA
Certara Certara
CERT
$ 12.12 -0.53 % $ 1.94 B usaUSA